Recently Lonsdale1 has described briefly a six-year-old boy who had recurrent episodes of cerebellar ataxia and a persistent elevation of alanine and pyruvate in blood. However, the site of biochemical lesion of the disorder remains unsolved. In process of screening for aminoaciduria, we also found a similar case associated with hyperalaninemia and pyruvicemia.
patient. The other sister was living and well. The patient showed a slow progress in mental and motor function since the infancy. During the infancy she had often vomiting. There was no history of convulsions or severe illness.
On admission at the age of 9 years, the patient showed mental retardation and motor dysfunction of severe degree. She was able to sit alone but unable to stand or walk. The extremities were somewhat rigid and the deep tendon reflexes were weak. EEG showed findings of hypsarrhythmia.
Thin-layer chromatograms of serum amino acids showed an increase in alanine. The concentration of serum alanine was found to range from 5.0 to 8.0mg per 100 ml on repeated examinations (normal value; 1.90 to 5.40mg per 100ml). The other amino acids in serum were within normal limits. Fasting blood glucose was 80mg per 100ml. Blood pyruvate levels were 2.9 to 4.1mg per 100ml (normal value; 0.5 to 1.5mg per 100ml). Blood lactate levels were 16.6 to 23.3mg per 100ml (normal values; 10 to 20mg per 100ml).
Paperchromatography of urinary organic acids revealed a remarkable spot of pyruvic acid but no abnormal spots were detected otherwise.
Serum alanine levels following the alanine loading showed an almost normal clearance curve except for the elevation of base level. Glucose tolerance test was normal. But the patient showed a significant rise of blood pyruvate and lactate after glucose loading as compared with controls. The activity of glutamic-pyruvic transaminase in the liver from the patient was found to be normal.
There was no difference in the in vitro lactate production from glucose by erythrocytes between the patient and controls. These findings suggest that the metabolic lesion of the disorder may lie in the entrance of pyruvate into the TCA cycle or the gluconeogenetic pathway .
Therefore, the liver biopsy specimen from the patient was studied for decarboxyla tion of pyruvate and pyruvate carboxylase. Decarboxylation of pyruvate was assayed by determining the formation of 14CO2 from pyruvate-1-14C . Pyruvate carboxylase was assayed by determining the incorporation of 14CO2 to oxaloacetate according to Utter and Keech.2 The patient's liver showed a definitely diminished activity of pyruvate carboxylase and normal activity of pyruvate decarboxyla tion (cf, Table 1 ). These results indicate that this particular disorder may be due to a partial defect in pyruvate carboxylase and hyperalaninemia is a secondary phenomenon due to the elevation of pyruvate. 
